Orion Partners with Shilpa Biocare to Launch Virus-Free Recombinant Human Albumin in Europe

Orion has entered into a partnership with Shilpa Biocare to introduce recombinant human albumin in Europe. The product, developed by Shilpa Biocare, is a key plasma protein used in various medical applications. It is produced using a non-human expression system, which allows for scalable production while ensuring high safety standards and virus-free manufacturing.

Recombinant human albumin plays an essential role in medical treatments and procedures, including drug formulation and delivery systems. The use of a non-human expression system eliminates the risk of contamination from human-derived pathogens, enhancing its safety profile. This collaboration marks a significant step in expanding access to this critical protein across European markets.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: Got it! Please provide the date you’d like me to format, and I’ll convert it for you.

Related posts:

Drug Patent Litigation: Costs Include R&D Delays and Workforce Reductions Serotonin Signals the Brain’s Best Guess About Future Rewards Pharmacy Experts Present Framework for Mentorship and Leadership Development in Palliative Care at 2025 SPPCP Virtual Conference Pharmaceutical Industry Adopts Advanced Manufacturing and Real-Time Data to Address Drug Shortages

Author

Mark Chiang